SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

MTR-106

Cat. No.:	HY-148953
CAS No.:	1639357-93-9
Molecular Formula:	$C_{28}H_{27}N_7O_2S$
Molecular Weight:	525.62
Target:	DNA/RNA Synthesis; G-quadruplex; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 2 mg/mL (3.81 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.9025 mL	9.5126 mL	19.0252 mL
	5 mM	---	---	---
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

MTR-106 is a potent and orally active G-quadruplex stabilizer and RNA polymerase I inhibitor. MTR-106 induces apoptosis and inhibits cell growth. MTR-106 can be used in research of cancer[1].

In Vitro

MTR-106 (0-100 μM; 7 d) has antitumor activity in both HR-deficient cells and PARPi-resistant cells[1].
MTR-106 (0-100 μM; 7 d) induces apoptosis, cell cycle arrest and DNA damage[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	HR-deficient and PARPi-resistant cancer cells
Concentration:	0-100 μM
Incubation Time:	7 days
Result:	Inhibited the viability of HR-deficient cells and PARPi-resistant cells in a dose-dependent nanner.

Cell Cycle Analysis[1]

Cell Line:	Capan-1 cells
Concentration:	0.1, 0.3, and 1 μM
Incubation Time:	24 hours
Result:	Increased in cells in G2/M, accompanied by a reduction in cell numbers in G1.

Western Blot Analysis[1]

Cell Line:	Capan-1 cells
Concentration:	1, 5, and 10 μM
Incubation Time:	24 hours
Result:	Increased the cleaved caspases 3, 7, and 9 and cleaved PARP in a dose-dependent manner.

In Vivo

MTR-106 (10-30 mg/kg; p.o.; twice a week, for 29 days) suppresses the tumor growth of BRCA-deficient and PARPi-resistant xenografts in nude mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BRCA-deficient and PARPi-resistant xenografts in nude mice[1]
Dosage:	10, 20, and 30 mg/kg
Administration:	oral administration; twice a week, for 29 days
Result:	Inhibited tumor growth in a dose-dependent manner.

REFERENCES

[1]. Li MZ, et, al. Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers. Invest New Drugs. 2021 Oct;39(5):1213-1221.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA